ArQule Inc. priced a public offering of 7 million shares of common stock at $6.15 per share to boost research and development of its pipeline of cancer products. The offering, which is expected to close Jan. 25, grants underwriters a 30-day option to purchase up to 1.05 million additional shares to cover overallotments.